Anatara Lifesciences logo

Anatara Lifesciences(ASX) ANR

Market CapA$2.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-98%
5 Year-94%
1 Year-40%
1 Month+0%
A$0.01
+0.00%
+0.00Today
Anatara Lifesciences last closing stock price
MetricPriceDate
Last closeAUD 0.012026-10-09
Anatara Lifesciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.012026-10-01
1 month+0%AUD 0.012026-09-09
3 month-10%AUD 0.012026-06-30
Year to date-35.71%AUD 0.012025-12-31
1 year-40%AUD 0.022025-10-09
3 year-67.86%AUD 0.032023-10-09
5 year-94%AUD 0.152021-10-08
Since inception-97.64%AUD 0.382014-10-16

Anatara Lifesciences Financials at a Glance

Market Cap

A$2.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$887.20K

Net Income (TTM)

-A$2.49M

EPS (TTM)

-A$0.00

P/E Ratio

-2.65

Dividend

A$0.00

Beta (Volatility)

0.38 (Low)

Price

A$0.01

Volume

110

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.01

52-Week Range

A$0.01 - A$0.02

Estimated Earnings Date

Feb 24, 2027

ANR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Anatara Lifesciences

Anatara Lifesciences Ltd is an Australian biotechnology company dedicated to researching, developing, and commercializing scientifically-validated therapies for digestive system ailments in both humans and animals. The company focuses on innovative solutions that address gastrointestinal conditions, aiming to improve health outcomes through its proprietary products.

Products and Services
  • Gastrointestinal ReProgramming (GRP) for human gastrointestinal conditions
  • 3FDC, targeting anxiety, stress, and depression
  • Detach and BONIFF for animal health, specifically for piglets
Growth Outlook
  • Recent product developments indicate potential for market expansion
  • Focus on addressing unmet needs in gastrointestinal health
  • Strategic partnerships may enhance distribution capabilities
Financial Highlights
  • Quarterly revenue of AUD 140,838, showing growth potential
  • Cash and cash equivalents of AUD 470,917, providing operational flexibility
  • Current ratio of 7.58, indicating strong short-term financial health
Anatara Lifesciences Ltd operates in a niche market with a focus on gastrointestinal health, which is increasingly recognized for its importance in overall well-being. The company's innovative product offerings, such as GRP and 3FDC, are designed to address significant health challenges, positioning Anatara as a key player in the biotechnology sector. The recent financial data reflects a commitment to growth, with a solid cash position and a favorable current ratio, suggesting the ability to meet short-term obligations while pursuing long-term objectives. As the company continues to develop its product pipeline and explore strategic partnerships, it may enhance its market presence and drive future revenue growth.
AI Generated • Oct 3, 2026

Industry

Biotechnology

CEO

David Lionel Brookes, PhD

Headquarters

Adelaide, SA 5000, AU

ANR Financials

Key Financial Metrics (TTM)

Gross Margin

17.26%

Operating Margin

-890.03%

Net Income Margin

-662.63%

Return on Equity

-101.34%

Return on Capital

-176.17%

Return on Assets

-113.75%

Earnings Yield

-37.74%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$2.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

316.31M

Volume

110

Avg. Volume

55.24K

Financials (TTM)

Gross Profit

-A$487.49K

Operating Income

-A$2.81M

EBITDA

-A$2.81M

Operating Cash Flow

-A$1.92M

Capital Expenditure

A$6.00

Free Cash Flow

-A$1.92M

Cash & ST Invst.

A$470.92K

Total Debt

A$0.00

Anatara Lifesciences Performance Analysis

Anatara Lifesciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Anatara Lifesciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31291.8%
Q42025-06-30-57.4%
Q22025-12-31-100.0%
Q42026-06-30N/A
Anatara Lifesciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.02-40.1%
20242024-06-30AUD -0.01-50.0%
20252025-06-30AUD -0.01-1.0%
20262026-06-30AUD -0.00-64.6%
Anatara Lifesciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-34.1%
Q42025-06-3067.8%
Q22025-12-31-10.5%
Q42026-06-3038.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$140.84K

+151.6%

Gross Profit

A$24.39K

+103.6%

Gross Margin

17.32%

N/A

Market Cap

A$2.85MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$406.69K

N/A

Employees

7

N/A

Net Income

-A$418.26K

+45.8%

EBITDA

-A$563.08K

+27.4%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$470.92K

-52.1%

Total Debt

A$0.00

N/A

Accounts Receivable

A$334.75K

-50.1%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-1.14%

N/A

Return on Invested Capital

-1.76%

N/A

Free Cash Flow

-A$621.29K

+35.2%

Operating Cash Flow

-A$621.29K

+35.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EXL.AXElixinol Wellness Limited
A$0.01+0.00%
CTQ.AXCareteq Limited
A$0.01+0.00%
IBX.AXImagion Biosystems Limited
A$0.01+0.00%
BIT.AXBiotron Limited
A$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About ANR

What is the current price of Anatara Lifesciences?

Anatara Lifesciences is trading at A$0.01 per share.

What is the 52-week range for Anatara Lifesciences?

Over the past 52 weeks, Anatara Lifesciences has traded between A$0.01 and A$0.02.

How much debt does Anatara Lifesciences have?

As of the most recent reporting period, Anatara Lifesciences reported total debt of A$0.00.

How much cash does Anatara Lifesciences have on hand?

Anatara Lifesciences reported A$470.92K in cash and cash equivalents in its most recent financial results.

What is Anatara Lifesciences’s dividend yield?

Anatara Lifesciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.